PAZOPANIB CLINICAL TRIAL

ABOUT THE RANDOMIZED TRIAL FOR PAZOPANIB IN HHT-RELATED BLEEDING

Researchers want to determine if the investigational drug, Pazopanib, will lessen nosebleed severity in patients with Hereditary Hemorrhagic Telangiectasia (HHT). This 24-week randomized trial for HHT-related bleeding will occur across about 12 research centers across the United States.

Patients will either be provided active drug or a placebo (sugar - inactive pill) and be tested for nosebleed severity throughout the trial. Investigators will also test for blood loss, and as always, safety.

Adult patients with HHT in the U.S. are eligible to participate if they have nose bleeding of at least 20 min per week plus hemoglobin level <12 in women or <13 in men OR average hemoglobin levels less than 10 plus nose bleeding of at least 5 min per week.

The Pazopanib trial is funded by Cure HHT with support from a grant from the U.S. Department of Defense. Pazopanib is an oral medication currently FDA approved for the treatment of certain cancers. For the HHT study, it is an experimental drug at 1/5 the cancer dose.

At the conclusion of the 24-week randomized study, there is an option for patients who received placebo to receive Pazopanib for an extension of the clinical trial for another 24 weeks.

OBJECTIVES

Primary Objective: To determine efficacy of Pazopanib compared to placebo for the reduction in severity of epistaxis (nosebleed duration) OR in severity of anemia (increase in hemoglobin) throughout the 24 weeks of the treatment period.

Secondary Objectives: To determine the safety and lifestyle effect of treatment with pazopanib (change in epistaxis severity and transfusion frequency) during the 24-48 weeks of treatment.
• Age 18-85
• Definite or probable* diagnosis of hereditary hemorrhagic telangiectasia, defined as having at least 3 of the following criteria:
  o Spontaneous and recurrent epistaxis.
  o Multiple telangiectasias at characteristic sites: lips, oral cavity, fingers, nose.
  o Visceral lesions: GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs.
  o A first degree relative with hereditary hemorrhagic telangiectasia according to these criteria.
  o *Probable diagnosis is two definite criteria and additional characteristics which are highly suggestive of HHT (must be discussed with medical monitoring team).
• Any use of IV iron and/or blood transfusions with consideration as stable for 12 weeks prior to test product initiation.
• Must agree not to undergo cautery of nasal telangiectasias or to start new therapies for HHT while on study.
• Women of non-childbearing potential; women of childbearing potential with agreement to practice abstinence or to use double method contraception until 4 weeks after drug termination with pregnancy tests prior to initiation and every 3 weeks after
• Capable of giving signed informed consent.
• Able and willing to return for outpatient visits at the protocol specified intervals.
• Able and willing to complete blood pressure monitoring at home.
• Able and willing to complete daily patient reported outcome measurements at home.

Must meet all of the inclusion criteria for either one of the below-listed cohorts:

**Severe Anemia Cohort:**

- Anemia mainly due to HHT (in the judgment of the PI) with average hemoglobin <10 g/dL regardless of gender. Epistaxis averaging at least 5 minutes per week over the six-week baseline and is generally stable in the clinical judgment of the Investigator.

**Severe Epistaxis Cohort:**

- Anemia mainly due to HHT (in the judgment of the PI) with hemoglobin < 12 g/dL in women or < 13 g/dL in men.
- Epistaxis averaging at least 20 minutes per week over the 6-week baseline and is generally stable in the clinical judgment of the Investigator.

**EXCLUSION CRITERIA**

• Participant has known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Pazopanib that in the opinion of the investigator contradicts their participation.
• Currently has incompletely treated cerebral arterio-venous malformations (AVMs) or cerebral arteriovenous fistulae (AVFs) that are symptomatic or have high-risk features detected on either MRI/MRA or digital subtraction angiography. (Note: MRI scan does not need to be repeated at screening if AVMs, arterio-venous fistulas were absent on a scan at age ≥ 18 years).
• Currently has perfused pulmonary AVMs with feeding artery diameter ≥ 3mm.
• Known significant bleeding sources other than nasal or gastrointestinal.
• Systemic use of a vascular endothelial growth factor inhibitor in the past 4 weeks, or systemic use of bevacizumab in the 6 weeks prior to enrollment due to its longer half-life.
• Active and recent onset of clinically significant diarrhea.
• Current or recent (in the last 5 years) malignancies (except non-melanoma skin cancers)
• Participant has had major surgery (e.g. surgical ligation of an AVM) or trauma within 28 days or had minor surgical procedures (e.g. central venous access line removal) within 7 days prior to dosing, the latter representing a recent wound, fracture or ulcer
• Participant has a planned surgery during the period to include active treatment and 6 weeks of follow up.
• Participant has clinically significant gastrointestinal abnormalities (other than hereditary hemorrhagic telangiectasia related vascular lesions).
• Participant during the 6 months prior to first dose of study drug has a history of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism, untreated deep vein thrombosis (DVT), myocardial infarction, or any other thrombotic event.
• Presence of intrinsic heart disease as evidenced by any of the following: Echo derived left ventricular ejection fraction < 45%; Unstable obstructive CAD; history of MI, or CABG, or PCI in the last 6 months; Infiltrative and/or restrictive cardiomyopathies; Significant pericardial disease; or clinical heart failure with more than moderate mitral valve or aortic valve disease.
• Unable or unwilling to discontinue use of prohibited medications for at least 14 days or 5 half-lives of a drug ( whichever is longer) prior to the randomization and for the duration of the study. List of prohibited drugs found in 6.5.2 of study protocol.
• The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the start of randomization: 4 weeks, 4 half-lives or the duration of the biological effect of the investigational product ( whichever is longer).
• QT corrected interval >450 msec for men, >460 msec for women, based on one tracing if clearly below this cutoff. However, for those single tracking values above the listed thresholds, but within ~10 – 20 msec of the cutoff point, it is at the PI’s discretion to redo up to 2 more times during the screening/run-in phase to determine eligibility.
  o History of familial prolonged QT.
  o Any concomitant medication which is known to prolong QT.
• Average baseline hemoglobin < 6 g/dL.
• Platelets < 75,000 µL.
• International normalized ratio (INR) >1.5 x upper limit of normal and activated partial thromboplastin time (aPTT) >1.5 x upper limit of normal.
• Alanine Transaminase (ALT) >2 x upper limit of normal.
• Bilirubin >1.5x upper limit of normal (isolated bilirubin >1.5x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin < 35%).
• Participant has poorly controlled hypertension (defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg).
• Substantive renal disease (eGFR <30 mL/min calculated using the Cockcroft-Gault formula)
• Thyroid stimulating hormone (TSH) > 1.5 x upper limit of normal.
• Urine protein to creatinine ratio > 0.4 mg protein/mg creatinine or > 400 mg protein/g creatinine.
• Neutrophil count <1000 /µL.

STUDY SITES

Approximately 12 HHT Centers of Excellence across the U.S. states will participate. Sites actively recruiting are listed below:

<table>
<thead>
<tr>
<th>Study Site</th>
<th>Contact Person</th>
<th>Email/Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Augusta University</td>
<td>Melissa James, RN</td>
<td><a href="mailto:mejames@augusta.edu">mejames@augusta.edu</a></td>
</tr>
<tr>
<td>Cleveland Clinic</td>
<td>Joanne Baran</td>
<td><a href="mailto:BARANJ2@ccf.org">BARANJ2@ccf.org</a></td>
</tr>
<tr>
<td>John Hopkins University</td>
<td>Eugene Bosworth</td>
<td><a href="mailto:eboswor1@jhmi.edu">eboswor1@jhmi.edu</a></td>
</tr>
<tr>
<td>Massachusetts General Hospital</td>
<td>Hanny Al-Samkari, MD</td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>Sue Donlinger</td>
<td><a href="mailto:donlinger.sueann@mayo.edu">donlinger.sueann@mayo.edu</a></td>
</tr>
<tr>
<td>Oregon Health &amp; Science University</td>
<td>Lori Russell BSN CCRP</td>
<td><a href="mailto:watsonlo@ohsu.edu">watsonlo@ohsu.edu</a></td>
</tr>
<tr>
<td></td>
<td>Eleanor Lottsfeldt</td>
<td><a href="mailto:lottsfel@ohsu.edu">lottsfel@ohsu.edu</a></td>
</tr>
<tr>
<td>University of California, Los Angeles</td>
<td>Victoria Rueda</td>
<td><a href="mailto:vrueda@mednet.ucla.edu">vrueda@mednet.ucla.edu</a></td>
</tr>
<tr>
<td>University of Colorado</td>
<td>Johan Allingmon</td>
<td><a href="mailto:johan.allingmon@cuanschutz.edu">johan.allingmon@cuanschutz.edu</a></td>
</tr>
<tr>
<td>Institution</td>
<td>Contact Person</td>
<td>Email</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>---------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>University of North Carolina at Chapel Hill</td>
<td>Mason Donaldson</td>
<td><a href="mailto:masdonal@email.unc.edu">masdonal@email.unc.edu</a></td>
</tr>
<tr>
<td>University of Utah</td>
<td>Mac McPherson, CRC</td>
<td><a href="mailto:jamil.mcpherson@hsc.utah.edu">jamil.mcpherson@hsc.utah.edu</a></td>
</tr>
<tr>
<td>Washington University in St. Louis</td>
<td>Kristine Kempf</td>
<td><a href="mailto:kempf@wustl.edu">kempf@wustl.edu</a></td>
</tr>
<tr>
<td>Yale</td>
<td>Katharine Henderson</td>
<td><a href="mailto:katharine.henderson@yale.edu">katharine.henderson@yale.edu</a></td>
</tr>
</tbody>
</table>

**SCHEDULE OF EVENTS**

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total duration</strong></td>
<td>8-15 months</td>
</tr>
<tr>
<td><strong># Study Visits</strong></td>
<td>2 in-person visits at the start and week 24; Virtual visits every 3 weeks (22 total)</td>
</tr>
<tr>
<td><strong>Drug</strong></td>
<td>Take study drug every day</td>
</tr>
<tr>
<td><strong>Diaries / Surveys</strong></td>
<td>Record blood pressure and nosebleeds every day; Fill out electronic questionnaires every 3 weeks</td>
</tr>
<tr>
<td><strong>Lab</strong></td>
<td>Blood and urine test at local lab every 3 weeks</td>
</tr>
<tr>
<td><strong>Other tests</strong></td>
<td>Home electrocardiogram every 6 weeks</td>
</tr>
</tbody>
</table>
Nothing for most patients.

- Study drug and regularly scheduled lab will be provided for free.
- Travel expenses will be partially compensated based on distance traveled.
- Blood pressure cuff and EKG device will be provided for free.

The most common risks of Pazopanib include increased blood pressure, increased liver enzymes in the blood, changes to the heart rhythm, infections – sometimes serious, gastrointestinal symptoms like diarrhea, low energy, and protein in the urine.

The Pazopanib study is registered with clinicaltrials.gov. More information on the study design and status can be found here: https://www.clinicaltrials.gov/ct2/show/NCT03850964?cond=hereditary+hemorrhagic+telangiectasia+Pazopanib&draw=2&rank=2